Kwality Pharma targets ₹850 cr by FY28, bets ₹270 cr on oncology and biosimilars
The company moved its biosimilar focus from Alteplase to Pembrolizumab and set a 30% EBITDA margin target for FY29.
What's new
- Management set a new revenue target of ₹800-850 crore for FY28, building on its ₹1,000 crore aspiration for FY29.
- The company is shifting its biosimilar pipeline focus from Alteplase to Pembrolizumab (a Keytruda generic).
- Regulated-market registrations in Germany for its products are expected within months.
Why this matters
Kwality is moving from a record ₹503 crore revenue year into a phase of aggressive, capital-intensive expansion. The pivot to Pembrolizumab, a high-value oncology drug, and the capex plan signal a strategic bet on complex biologics. The new FY28 guidance implies nearly 70% growth from FY26, making execution on this pipeline critical.
What we're watching
- Timelines for the Erythropoietin biosimilar regulatory submission by year-end.
- Progress on the Algeria joint venture funding clinical trials for the Pembrolizumab generic.
- Margin trajectory towards the stated 30% EBITDA target.
The full read
Kwality Pharmaceuticals finished a record year with ₹503 crore in revenue and ₹67 crore profit, but the call was about the future. Management unveiled a new FY28 target of ₹800-850 crore, implying roughly 70% growth in two years, and set an EBITDA margin goal of 30% for FY29. To get there, it's committing ₹260-270 crore in capex to oncology capacity, hormones, and biosimilars. The biggest move is a pipeline pivot: Kwality dropped Alteplase to develop a Pembrolizumab generic, a far bigger commercial prize. An Algeria JV will help fund the trials. On the commercial side, German registrations are imminent. The playbook is clear: use cash from a strong existing business to fund a push into complex biologics.
Questions answered
- What are Kwality's new financial targets?
- Management set an FY28 revenue target of ₹800-850 crore and repeated its ₹1,000 crore aspiration for FY29. EBITDA margins are forecast to reach 30% by FY29.
- Where is the company directing its capital expenditure?
- It is spending ₹260-270 crore on expanding oncology capacity, building a hormone plant, and developing three biosimilar antibodies.
- What changed in the biosimilar pipeline?
- The company shifted its focus from Alteplase to developing a generic version of Pembrolizumab (Keytruda). A joint venture in Algeria will help fund the clinical trials.
- What is the near-term milestone for regulated markets?
- High-margin registrations in Germany for its products are expected within months, which would provide access to a key regulated market.